Search results
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks· 3 days agoFree Report) reported adjusted earnings of $2.07 per share for first-quarter 2024, beating the Zacks Consensus Estimate of $1.94. Earnings rose 48% year over year on a reported basis and 54% ...
Merck shares target raised on strong Q1 performance By Investing.com
Investing.com· 2 days agoOn Thursday, Truist Securities adjusted the stock price target for Merck (NYSE:MRK), a global...
Merck stock gains on Q1 2024 beat (NYSE:MRK)
Seeking Alpha· 2 days agoMerck (MRK) stock gains as the company posts better than expected Q1 2024 financials with strong sales growth from its cancer medicine Keytruda. Read...
Merck (MRK) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 2 days agoThe following revenue comments will be on an ex exchange basis. Our Human Health business continued its momentum with double-digit growth of 13% driven...
Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks· 3 days agoAlthough the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics ...
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
CNBC· 2 days agoMerck on Thursday reported first-quarter revenue and adjusted earnings that topped expectations as...
Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda
Reuters via AOL· 2 days ago(Reuters) -Merck & Co on Thursday raised its annual profit and revenue forecast on the back of...
Merck highlights progress on HIV, hypertension, cervical cancer drugs
WFMZ Eastern Pennsylvania and Western New Jersey· 2 days agoMerck got off to an excellent start in the first quarter of 2024. Wall Street met the news with...
Analyst Report: Merck & Co., Inc.
Morningstar Research via Yahoo Finance· 2 days agoThe company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Zacks via Yahoo Finance· 2 days agoWith continued label expansion into new indications, particularly earlier-stage launches, Keytruda...
